EVNIN LUKE sold $47K of HOWL (indirect holdings)
EVNIN LUKE sold 157,084 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.30 on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 157,084 shares at $0.3000/share, leaving 143,199 shares after the transaction.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of other catalysts make this more of a monitoring item than a trade trigger.
What to watch
The filing is indirect holdings; without context on total insider ownership changes across time, the incremental signal is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics, Inc.
Ticker impact
SEC Form 4 shows director EVNIN LUKE sold 157,084 HOWL shares in an open-market transaction under a 10b5-1 plan.
Likely limited immediate price impact; any effect would be sentiment-driven and small versus broader fundamentals.
The filing is a routine insider sale (code S) with a pre-arranged 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.
Market effects
No sector read-across; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerWerewolf Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure (HOWL).
- insiderEVNIN LUKE
Director who sold shares under a pre-arranged 10b5-1 plan.
